Membrane-anchored Cbl suppresses Hck protein-tyrosine kinase mediated cellular transformation

Christopher J Howlett1, Stephen M Robbins

  • 1Department of Oncology, The University of Calgary, 3330 Hospital Drive N.W., Calgary, Alberta T2N-4N1, Canada.

Oncogene
|March 16, 2002
PubMed

Insights

The Cbl proto-oncogene degrades Src-family kinase Hck, a key molecule in cell growth. This finding reveals a new way to control Src-family kinases and offers potential cancer therapy strategies.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Oncogenesis

Background:

  • Proto-oncogene Cbl acts as a negative regulator in growth factor receptor signaling pathways.
  • Homologues of Cbl, such as Sli-1 in C. elegans and D-Cbl in Drosophila, are also involved in signaling regulation.

Purpose of the Study:

  • To investigate the role of Cbl in regulating Src-family kinase Hck.
  • To determine if Cbl can target Hck for degradation and suppress Hck-mediated cellular transformation.

Main Methods:

  • Utilized ectopic expression of a membrane-anchored Cbl allele in murine fibroblasts.
  • Assessed cellular morphology, anchorage-independent growth, and tyrosine phosphorylation levels.
  • Investigated ubiquitination and degradation pathways using proteasome inhibitors.
  • Performed co-immunoprecipitation to study Cbl-Hck interactions.

Main Results:

  • Cbl targets Src-family kinase Hck for ubiquitination and proteasomal degradation.
  • Ectopic expression of membrane-anchored Cbl reverted Hck-mediated cellular transformation.
  • Cbl-mediated degradation of Hck requires an intact RING finger and proteasome activity.
  • Both activated and kinase-inactive Hck interact with Cbl and are degraded.

Conclusions:

  • Cbl negatively regulates Hck activity by promoting its degradation.
  • This mechanism provides an alternative pathway for controlling Src-family kinase signaling.
  • Cbl's ability to suppress Hck suggests potential therapeutic applications in cancers driven by aberrant signaling pathways.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...